Durvalumab versus placebo with chemoradiotherapy for locally advanced cervical cancer (CALLA): a randomised, double-blind, phase 3 trial
Journal
The Lancet. Oncology
Journal Volume
24
Journal Issue
12
Date Issued
2023-12
Author(s)
Monk, Bradley J
Toita, Takafumi
Wu, Xiaohua
Vázquez Limón, Juan C
Tarnawski, Rafal
Mandai, Masaki
Shapira-Frommer, Ronnie
Mahantshetty, Umesh
Del Pilar Estevez-Diz, Maria
Zhou, Qi
Limaye, Sewanti
Godinez, Francisco J Ramirez
Oppermann Kussler, Christina
Varga, Szilvia
Valdiviezo, Natalia
Aoki, Daisuke
Leiva, Manuel
Lee, Jung-Yun
Sulay, Raymond
Kreynina, Yulia
Rey, Felipe
Rong, Yi
Ke, Guihao
Wildsmith, Sophie
Lloyd, Andrew
Dry, Hannah
Tablante Nunes, Ana
Mayadev, Jyoti
Abstract
Concurrent chemoradiotherapy has been the standard of care for locally advanced cervical cancer for over 20 years; however, 30-40% of treated patients have recurrence or progression within 5 years. Immune checkpoint inhibition has improved outcomes for patients with PD-L1 positive metastatic or recurrent cervical cancer. We assessed the benefit of adding durvalumab, a PD-L1 antibody, with and following chemoradiotherapy for locally advanced cervical cancer.
SDGs
Type
journal article